Ritlecitinib
 | |
| Clinical data | |
|---|---|
| Trade names | Litfulo |
| Other names | PF-06651600 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H19N5O |
| Molar mass | 285.351 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss).[1] Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.[1][2][3]
Ritlecitinib was approved for medical use in the United States in June 2023.[1][4]
Medical uses
Ritlecitinib is indicated for the treatment of severe alopecia areata.[1]
References
- ^ a b c d e "LITFULOTM (ritlecitinib) capsules, for oral use". Pfizer, Inc.
- ^ "Ritlecitinib". Inxight Drugs. Retrieved 24 June 2023.
- ^ Ramírez-Marín HA, Tosti A (February 2022). "Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata". Drug Design, Development and Therapy. 16: 363–374. doi:10.2147/DDDT.S334727. PMC 8860347. PMID 35210753.
- ^ "FDA Approves Pfizer's Litfulo (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata" (Press release). Pfizer. 23 June 2023. Retrieved 24 June 2023 – via Business Wire.
Further reading
- Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. (April 2022). "Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers". The Journal of Allergy and Clinical Immunology. 149 (4): 1318–1328. doi:10.1016/j.jaci.2021.10.036. PMID 34863853. S2CID 244824663.
- King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. (May 2023). "Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial". Lancet. 401 (10387). London, England: 1518–1529. doi:10.1016/S0140-6736(23)00222-2. PMID 37062298. S2CID 258114404.
External links
- Clinical trial number NCT03732807 for "PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |